Br J Cancer:肥胖、代谢健康与乳腺癌发病风险相关

2021-10-13 xiaozeng MedSci原创

肥胖作为全球主要的一大公共卫生问题,也是慢性病的主要危险因素,包括心血管疾病(CVD)以及某些类型的癌症。

肥胖作为全球主要的一大公共卫生问题,也是慢性病的主要危险因素,包括血管疾病(CVD)以及某些类型的癌症。既往的流行病学研究结果显示,肥胖会增加绝经后妇女罹患乳腺癌的风险,但却与绝经前妇女的患病风险呈负相关。

最近的研究表明,在亚洲女性中,肥胖与乳腺癌患病风险存在着异质性关联。与一般的肥胖症相似的是,代谢综合征(MetS)与绝经后妇女患乳腺癌风险的升高相关,但与绝经前妇女无关。


既往研究显示,肥胖和MetS是由一些常见的生物学反应所引起的,如胰岛素抵抗、炎症反应、性激素代谢和能量代谢等。因此,肥胖和MetS或与癌症的发病风险具有相似的关联性。


在该研究中,研究人员旨在调查MetS、肥胖以及二者作为代谢性肥胖表型的组合与东亚绝经后妇女乳腺癌患病风险之间的关联性。

该研究共纳入了2009年至2010年期间接受过国家医疗保健服务中线的健康检查的3,095,336名年龄在40-79岁的绝经后无癌症女性。并记录这些女性的浸润性乳腺癌发病率,随访至2018年。研究人员主要分析了肥胖(体重指数BMI≥25 kg/m2)、MetS与疾病发病风险的相关性。


结果显示,肥胖、MetS与乳腺癌的发病风险相关,但当肥胖和MetS的影响相互调整后,该相关性减弱,尤其是MetS的相关性。在调整BMI后,研究人员发现,只有空腹血糖水平和腰围的升高才与患乳腺癌发病风险升高相关。


进一步的研究显示,相比于代谢健康的正常体重女性,代谢不健康的正常体重女性、代谢健康的肥胖女性以及代谢不健康的肥胖女性的乳腺癌患病风险升高。

研究流程图

总而言之,该研究结果揭示,肥胖、MetS与绝经后妇女乳腺癌患病风险的升高独立相关。因此,鼓励绝经后妇女控制体重和自身代谢健康。


原始出处:

Park, B., Kim, S., Kim, H. et al. Associations between obesity, metabolic health, and the risk of breast cancer in East Asian women. Br J Cancer (22 September 2021).

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1799908, encodeId=14d91e9990825, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Thu Jun 30 18:16:53 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571410, encodeId=7be915e14100a, content=<a href='/topic/show?id=fcf425411da' target=_blank style='color:#2F92EE;'>#代谢健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25411, encryptionId=fcf425411da, topicName=代谢健康)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7a515732936, createdName=宋威, createdTime=Thu Oct 14 15:16:53 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060012, encodeId=cafd1060012dd, content=好文章,值得分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Wed Oct 13 07:06:54 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060008, encodeId=d4f910600083f, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Wed Oct 13 06:55:42 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059997, encodeId=3238105999ee2, content=不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Wed Oct 13 06:21:50 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059994, encodeId=fac8105999440, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b075626711, createdName=ms2000001527205767, createdTime=Wed Oct 13 06:13:47 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1799908, encodeId=14d91e9990825, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Thu Jun 30 18:16:53 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571410, encodeId=7be915e14100a, content=<a href='/topic/show?id=fcf425411da' target=_blank style='color:#2F92EE;'>#代谢健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25411, encryptionId=fcf425411da, topicName=代谢健康)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7a515732936, createdName=宋威, createdTime=Thu Oct 14 15:16:53 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060012, encodeId=cafd1060012dd, content=好文章,值得分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Wed Oct 13 07:06:54 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060008, encodeId=d4f910600083f, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Wed Oct 13 06:55:42 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059997, encodeId=3238105999ee2, content=不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Wed Oct 13 06:21:50 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059994, encodeId=fac8105999440, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b075626711, createdName=ms2000001527205767, createdTime=Wed Oct 13 06:13:47 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1799908, encodeId=14d91e9990825, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Thu Jun 30 18:16:53 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571410, encodeId=7be915e14100a, content=<a href='/topic/show?id=fcf425411da' target=_blank style='color:#2F92EE;'>#代谢健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25411, encryptionId=fcf425411da, topicName=代谢健康)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7a515732936, createdName=宋威, createdTime=Thu Oct 14 15:16:53 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060012, encodeId=cafd1060012dd, content=好文章,值得分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Wed Oct 13 07:06:54 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060008, encodeId=d4f910600083f, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Wed Oct 13 06:55:42 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059997, encodeId=3238105999ee2, content=不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Wed Oct 13 06:21:50 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059994, encodeId=fac8105999440, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b075626711, createdName=ms2000001527205767, createdTime=Wed Oct 13 06:13:47 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-10-13 yangchou

    好文章,值得分享。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1799908, encodeId=14d91e9990825, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Thu Jun 30 18:16:53 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571410, encodeId=7be915e14100a, content=<a href='/topic/show?id=fcf425411da' target=_blank style='color:#2F92EE;'>#代谢健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25411, encryptionId=fcf425411da, topicName=代谢健康)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7a515732936, createdName=宋威, createdTime=Thu Oct 14 15:16:53 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060012, encodeId=cafd1060012dd, content=好文章,值得分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Wed Oct 13 07:06:54 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060008, encodeId=d4f910600083f, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Wed Oct 13 06:55:42 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059997, encodeId=3238105999ee2, content=不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Wed Oct 13 06:21:50 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059994, encodeId=fac8105999440, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b075626711, createdName=ms2000001527205767, createdTime=Wed Oct 13 06:13:47 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-10-13 学医无涯

    了解一下

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1799908, encodeId=14d91e9990825, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Thu Jun 30 18:16:53 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571410, encodeId=7be915e14100a, content=<a href='/topic/show?id=fcf425411da' target=_blank style='color:#2F92EE;'>#代谢健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25411, encryptionId=fcf425411da, topicName=代谢健康)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7a515732936, createdName=宋威, createdTime=Thu Oct 14 15:16:53 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060012, encodeId=cafd1060012dd, content=好文章,值得分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Wed Oct 13 07:06:54 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060008, encodeId=d4f910600083f, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Wed Oct 13 06:55:42 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059997, encodeId=3238105999ee2, content=不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Wed Oct 13 06:21:50 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059994, encodeId=fac8105999440, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b075626711, createdName=ms2000001527205767, createdTime=Wed Oct 13 06:13:47 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-10-13 仁术2021

    不错学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1799908, encodeId=14d91e9990825, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Thu Jun 30 18:16:53 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571410, encodeId=7be915e14100a, content=<a href='/topic/show?id=fcf425411da' target=_blank style='color:#2F92EE;'>#代谢健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25411, encryptionId=fcf425411da, topicName=代谢健康)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7a515732936, createdName=宋威, createdTime=Thu Oct 14 15:16:53 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060012, encodeId=cafd1060012dd, content=好文章,值得分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Wed Oct 13 07:06:54 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060008, encodeId=d4f910600083f, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Wed Oct 13 06:55:42 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059997, encodeId=3238105999ee2, content=不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Wed Oct 13 06:21:50 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059994, encodeId=fac8105999440, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b075626711, createdName=ms2000001527205767, createdTime=Wed Oct 13 06:13:47 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-10-13 ms2000001527205767

    0

相关资讯

BREAST CANCER RES TR:亚洲数据出炉!奈拉替尼对晚期乳腺癌疗效如何?

NALA试验的亚洲亚组患者分析:比较奈拉替尼+卡培他滨(N+C)与拉帕替尼+卡培他滨(L+C)在先前接受两种或以上HER2靶向治疗的HER2+转移性乳腺癌患者中的疗效

Breast Cancer Res:如何预测乳腺癌幸存者冠心病风险?看多基因风险评分啊!

心血管疾病是乳腺癌幸存患者中的长期风险因素,且随着乳腺癌疗法而增加。

日常用品所含的这3种物质,很可能是乳腺癌的帮凶!

Current Research in Toxicology:三种光刺激剂在MCF-7乳腺癌细胞移植小鼠中诱导乳腺肿瘤生长

体外重建患者的肿瘤器官什么鬼?乳腺癌精准治疗重大突破!

中国团队:乳腺癌类器官(PDO)可指导晚期乳腺癌患者的个性化治疗。

Br J Cancer:饮酒量大,乳腺癌患病风险高

在全球大多数的国家中,乳腺癌(BC)仍然是女性中最常被诊断出的癌症之一,其扰乱了数百万女性的生活健康。

中国已成癌症大国!肺癌死亡率飙升4倍,男性高于女性​

此次2020年的《全球癌症统计报告》 共涵盖全球185个国家、36种癌症。其主要内容包括6大部分:全球癌症分布、主要致癌因素、癌症的病理过程、社会因素对于癌症预防的影响、常见癌症的预防策略及其理论基础